Clinical Trial Update: Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery [Phase 1]

View source ↗

Summary

Phase 1 clinical study evaluating the combination of azacitidine and recombinant interferon alfa-2b in patients with unresectable stage III/IV melanoma or stage…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Interferon alfa-2b (interferon alfa-2b)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Recurrent Renal Cell Cancer | Phase 1 | Status: COMPLETED